Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Amortization of Deferred Charges (2024 - 2025)

BridgeBio Pharma (BBIO) has disclosed Amortization of Deferred Charges for 2 consecutive years, with -$4.5 million as the latest value for Q4 2025.

  • Quarterly Amortization of Deferred Charges fell 318.64% to -$4.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.1 million through Dec 2025, changed N/A year-over-year, with the annual reading at $7.5 million for FY2024, 16.2% down from the prior year.
  • Amortization of Deferred Charges hit -$4.5 million in Q4 2025 for BridgeBio Pharma, down from $506000.0 in the prior quarter.
  • In the past five years, Amortization of Deferred Charges ranged from a high of $2.1 million in Q4 2024 to a low of -$4.5 million in Q4 2025.